In 2026, learning management systems are not just “nice-to-have” training portals. They are operational infrastructur ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...